BioSymetrics

We collaborated with a group from Parent Project Muscular Dystrophy, from Leiden University Medical Center and University of Florida, to identify biomarkers of disease progression in Duchenne muscular dystrophy (#DMD). A preprint of our work is now available on medRxiv. Special thanks to Shahrzad Hosseini and Simon Eng for leading this work for BioSymetrics! See the preprint here: https://lnkd.in/d7jhJRWn

Join us as we celebrate the 5th anniversary of BioSymetrics' Canadian subsidiary this week! We started our Canadian operations in 2019 from a little office space in Toronto. Since then our Canadian team has expanded beyond Toronto, to Charlottetown on the east coast and Vancouver on the west coast! Our Canadian Machine Learning team has been at the forefront of various BioSymetrics technologies, including our proprietary Phenograph, Computer Vision, and MOA Miner platforms. Special thanks to Gabriel Musso, Victoria Catterson , and Kevin Ha for co-founding our Canadian team and paving the way for our future success!

At BioSymetrics, we have a team with diverse backgrounds and skillsets, based in various locations throughout North America. Over the coming months, we will highlight our team members and celebrate their journeys to their current roles at BioSymetrics through our Pheno-Type series. Follow us and stay tuned! #Biotech #AIDrugDiscovery #MachineLearning

We are delighted to kick off an exciting new collaboration with Christine Bear, PhD from Molecular Medicine at The Hospital for Sick Children (SickKids), to unlock targeted therapies for people with Cystic Fibrosis (CF). The recent breakthrough drug Trikafta™ has been transformative for patients with the F508del mutation on the CFTR gene: the most common cause of CF. But there are over 400 disease-causing gene variants of the CFTR gene, and not all patients with the F508del mutation respond to Trikafta™. Similarly, the SickKids CF Centre found that tissue samples carrying CF-causing mutations show considerable variability in Trikafta™ response size in the lab. This collaboration will use machine learning to sift through phenotypic and genetic data for responders and non-responders, to help identify those people who are most likely to benefit from Trikafta™ and emerging therapies. “The results of this project could be so impactful to the lives of those living with Cystic Fibrosis. I’m gratified to be involved in this important work.” —Victoria Catterson, VP of Data Science Research at BioSymetrics #CysticFibrosis #MachineLearning

Happy Canada Day and Happy U.S. Independence Day! We at BioSymetrics are a multinational company based in both Canada and the United States. With our #RemoteFirst philosophy, we have drawn in the best talent from all over North America – from our home bases of Toronto and New York to the Midwest, the Pacific Northwest, and the Eastern Seaboard and Atlantic Canada – to create a diverse team and an inclusive work environment! #CanadaDay #IndependenceDay #DiversityAndInclusion

Using ContingentAI™, we found Parkinson’s Disease (PD) phenoclusters from a clinical dataset from the Parkinson’s Progression Markers Initiative (PPMI). We saw distinct outcomes between Healthy Control (HC) patients, those with continued REM sleep behavioural disorder (RBD), and those with rapid progression of motor symptoms. Interestingly, cluster C8 has overwhelmingly female patients, whereas the PPMI dataset and PD in general skew towards males. With our Phenograph, we will follow-up on unique biomarkers for these clusters to better understand the biology driving these phenotypes. #ai #drugdiscovery #parkinsons #parkinsonsdisease

We recently used ContingentAI™, which optimizes the full machine learning workflow from preprocessing to modelling and analysis, to classify Parkinson’s Disease patients into phenoclusters that may respond better to a tailored therapeutic approach. Click through to learn more! https://lnkd.in/gRZwp-tR #ai #drugdiscovery

We’re at #BIO2024! Find Gabriel Musso, our Chief Scientific Officer, to learn more about our Elion platform for discovery and development of neurotherapeutics, as well as our epilepsy and Parkinson’s disease programs. Request a meeting with us via the partnering platform! #ai #drugdiscovery

We were delighted to be part of a Digital Global Innovation Cluster research project exploring federated machine learning (ML) on Parkinson’s Disease clinical data with our partners DNAstack and integrate.ai. Click through to find out more about about this approach and our results! https://lnkd.in/ge-YqtnY #ai #federatedml

Come find us at #BIO2024! Gabriel Musso, our Chief Scientific Officer, will be attending this year to talk about our Elion platform for discovery and development of neurotherapeutics, as well as the progress with our epilepsy and PD programs. Request a meeting with us via the partnering platform! #ai #drugdiscovery